Advertisement

CardioVascular and Interventional Radiology

, Volume 38, Issue 2, pp 401–408 | Cite as

Irreversible Electroporation (IRE) Fails to Demonstrate Efficacy in a Prospective Multicenter Phase II Trial on Lung Malignancies: The ALICE Trial

  • Jens Ricke
  • Julian H. W. Jürgens
  • Frederic Deschamps
  • Lambros Tselikas
  • Katja Uhde
  • Ortrud Kosiek
  • Thierry De Baere
Clinical Investigation

Abstract

Purpose

To assess safety and efficacy of irreversible electroporation (IRE) of lung malignancies.

Materials and Methods

Patients with primary and secondary lung malignancies and preserved lung function were included in this prospective single arm trial. Primary and secondary endpoints were safety and efficacy. Recruitment goal was 36 subjects in 2 centers. Patients underwent IRE under general anesthesia with probe placement performed in Fluoroscopy-CT. The IRE system employed was NanoKnife® (Angiodynamics). System settings for the ablation procedure followed the manufacturer’s recommendations. The Mann–Whitney U test was used to evaluate the correlation of nine technical parameters with local tumor control. Median follow up was 12 months.

Results

The expected efficacy was not met at interim analysis and the trial was stopped prematurely after inclusion of 23 patients (13/10 between both centers). The dominant tumor entity was colorectal (n = 13). The median tumor diameter was 16 mm (8–27 mm). Pneumothoraces were observed in 11 of 23 patients with chest tubes required in 8 (35 %). Frequently observed alveolar hemorrhage never led to significant hemoptysis. 14/23 showed progressive disease (61 %). Stable disease was found in 1 (4 %), partial remission in 1 (4 %) and complete remission in 7 (30 %) patients. The relative increase of the current during ablation was significantly higher in the group treated successfully as compared to the group presenting local recurrence (p < 0.05). Needle tract seeding was found in three cases (13 %).

Conclusions

IRE is not effective for the treatment of lung malignancies. We hypothesize that the energy deposition with current IRE probes is highly sensitive to air exposure.

Keywords

Interventional oncology Non-vascular interventions Irreversible electroporation (IRE) Lung/pulmonary Cancer 

Notes

Conflict of interest

Jens Ricke, Julian Jürgens, Frederic Deschamps, Lambros Tselikas, Katja Uhde, Ortrud Kosiek, and Thierry De Baere have no conflict of interest.

Statement of Human and Animal Rights

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Statement of Informed Consent

Informed consent was obtained from all individual participants included in the study.

References

  1. 1.
    Edd JF, Horowitz L, Davalos RV, Mir LM, Rubinsky B (2006) In vivo results of a new focal tissue ablation technique: irreversible electroporation. IEEE Trans Biomed Eng 53:1409–1415CrossRefPubMedGoogle Scholar
  2. 2.
    Rubinsky B (2007) Irreversible electroporation in medicine. Technol Cancer Res Treat 6:255–260CrossRefPubMedGoogle Scholar
  3. 3.
    Mir LM, Orlowski S, Belehradek J Jr, Paoletti C (1991) Electrochemotherapy potentiation of antitumour effect of bleomycin by local electric pulses. Eur J Cancer 27:68–72CrossRefPubMedGoogle Scholar
  4. 4.
    Neumann E, Schaefer-Ridder M, Wang Y, Hofschneider PH (1982) Gene transfer into mouse lyoma cells by electroporation in high electric fields. EMBO J 1:841–845PubMedCentralPubMedGoogle Scholar
  5. 5.
    Okino M, Mohri H (1987) Effects of a high-voltage electrical impulse and an anticancer drug on in vivo growing tumors. Jpn J Cancer Res 78:1319–1321PubMedGoogle Scholar
  6. 6.
    Pech M, Janitzky A, Wendler JJ et al (2011) Irreversible electroporation of renal cell carcinoma: a first-in-man phase I clinical study. Cardiovasc Interv Radiol 34:132–138CrossRefGoogle Scholar
  7. 7.
    Lu DS, Kee ST, Lee EW (2013) Irreversible electroporation: ready for prime time? Tech Vasc Interv Radiol 16:277–286CrossRefPubMedGoogle Scholar
  8. 8.
    Yeung ES, Chung MW, Wong K, Wong CY, So EC, Chan AC (2014) An update on irreversible electroporation of liver tumours. Hong Kong Med J 20(4):313–316PubMedGoogle Scholar
  9. 9.
    Charpentier KP (2012) Irreversible electroporation for the ablation of liver tumors: are we there yet? Arch Surg 147:1053–1061CrossRefPubMedGoogle Scholar
  10. 10.
    Dunki-Jacobs EM, Philips P, Martin RC (2014) Evaluation of resistance as a measure of successful tumor ablation during irreversible electroporation of the pancreas. J Am Coll Surg 218:179–187CrossRefPubMedGoogle Scholar
  11. 11.
    Scheffer HJ, Nielsen K, de Jong MC et al (2014) Irreversible electroporation for nonthermal tumor ablation in the clinical setting: a systematic review of safety and efficacy. J Vasc Interv Radiol 25:997–1011CrossRefPubMedGoogle Scholar
  12. 12.
    Wendler JJ, Pech M, Blaschke S et al (2012) Angiography in the isolated perfused kidney: radiological evaluation of vascular protection in tissue ablation by nonthermal irreversible electroporation. Cardiovasc Interv Radiol 35:383–390CrossRefGoogle Scholar
  13. 13.
    Wendler JJ, Pech M, Porsch M et al (2012) Urinary tract effects after multifocal nonthermal irreversible electroporation of the kidney: acute and chronic monitoring by magnetic resonance imaging, intravenous urography and urinary cytology. Cardiovasc Interv Radiol 35:921–926CrossRefGoogle Scholar
  14. 14.
    Wendler JJ, Porsch M, Huhne S et al (2013) Short- and mid-term effects of irreversible electroporation on normal renal tissue: an animal model. Cardiovasc Interv Radiol 36:512–520CrossRefGoogle Scholar
  15. 15.
    Little MW, Chung D, Boardman P, Gleeson FV, Anderson EM (2013) Microwave ablation of pulmonary malignancies using a novel high-energy antenna system. Cardiovasc Interv Radiol 36:460–465CrossRefGoogle Scholar
  16. 16.
    Yan TD, King J, Sjarif A, Glenn D, Steinke K, Morris DL (2006) Percutaneous radiofrequency ablation of pulmonary metastases from colorectal carcinoma: prognostic determinants for survival. Ann Surg Oncol 13:1529–1537CrossRefPubMedGoogle Scholar
  17. 17.
    Lencioni R, Crocetti L, Cioni R et al (2008) Response to radiofrequency ablation of pulmonary tumours: a prospective, intention-to-treat, multicentre clinical trial (the RAPTURE study). Lancet Oncol 9:621–628CrossRefPubMedGoogle Scholar
  18. 18.
    Lu DS, Yu NC, Raman SS et al (2005) Radiofrequency ablation of hepatocellular carcinoma: treatment success as defined by histologic examination of the explanted liver. Radiology 234:954–960CrossRefPubMedGoogle Scholar
  19. 19.
    Lee H, Jin GY, Han YM et al (2012) Comparison of survival rate in primary non-small-cell lung cancer among elderly patients treated with radiofrequency ablation, surgery, or chemotherapy. Cardiovasc Interv Radiol 35:343–350CrossRefGoogle Scholar
  20. 20.
    Bilal H, Mahmood S, Rajashanker B, Shah R (2012) Is radiofrequency ablation more effective than stereotactic ablative radiotherapy in patients with early stage medically inoperable non-small cell lung cancer? Interact CardioVasc Thorac Surg 15:258–265CrossRefPubMedCentralPubMedGoogle Scholar
  21. 21.
    Deodhar A, Monette S, Single GW Jr et al (2011) Percutaneous irreversible electroporation lung ablation: preliminary results in a porcine model. Cardiovasc Interv Radiol 34:1278–1287CrossRefGoogle Scholar
  22. 22.
    Ball C, Thomson KR, Kavnoudias H (2010) Irreversible electroporation: a new challenge in “out of operating theater” anesthesia. Anesth Analg 110:1305–1309CrossRefPubMedGoogle Scholar
  23. 23.
    Deodhar A, Dickfeld T, Single GW et al (2011) Irreversible electroporation near the heart: ventricular arrhythmias can be prevented with ECG synchronization. AJR Am J Roentgenol 196:W330–W335CrossRefPubMedGoogle Scholar
  24. 24.
    Wahl RL, Jacene H, Kasamon Y, Lodge MA (2009) From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med 50(Suppl 1):122S–150SCrossRefPubMedCentralPubMedGoogle Scholar
  25. 25.
    Scheffer HJ, Nielsen K, van Tilborg AA et al (2014) Ablation of colorectal liver metastases by irreversible electroporation: results of the COLDFIRE-I ablate-and-resect study. Eur Radiol 24(10):2467–2475CrossRefPubMedGoogle Scholar
  26. 26.
    Thomson KR, Cheung W, Ellis SJ et al (2011) Investigation of the safety of irreversible electroporation in humans. J Vasc Interv Radiol 22:611–621CrossRefPubMedGoogle Scholar
  27. 27.
    Usman M, Moore W, Talati R, Watkins K, Bilfinger TV (2012) Irreversible electroporation of lung neoplasm: a case series. Med Sci Monit 18:CS43–CS47CrossRefPubMedCentralPubMedGoogle Scholar
  28. 28.
    Ben-David E, Ahmed M, Faroja M et al (2013) Irreversible electroporation: treatment effect is susceptible to local environment and tissue properties. Radiology 269:738–747CrossRefPubMedCentralPubMedGoogle Scholar
  29. 29.
    Davalos RV, Mir IL, Rubinsky B (2005) Tissue ablation with irreversible electroporation. Ann Biomed Eng 33:223–231CrossRefPubMedGoogle Scholar
  30. 30.
    Rubinsky B, Onik G, Mikus P (2007) Irreversible electroporation: a new ablation modality—clinical implications. Technol Cancer Res Treat 6:37–48CrossRefPubMedGoogle Scholar
  31. 31.
    Daniels C, Rubinsky B (2009) Electrical field and temperature model of nonthermal irreversible electroporation in heterogeneous tissues. J Biomech Eng 131:071006CrossRefPubMedGoogle Scholar
  32. 32.
    Faroja M, Ahmed M, Appelbaum L et al (2013) Irreversible electroporation ablation: is all the damage nonthermal? Radiology 266:462–470CrossRefPubMedGoogle Scholar
  33. 33.
    Zhu JC, Yan TD, Morris DL (2008) A systematic review of radiofrequency ablation for lung tumors. Ann Surg Oncol 15:1765–1774CrossRefPubMedGoogle Scholar
  34. 34.
    Kashima M, Yamakado K, Takaki H et al (2011) Complications after 1000 lung radiofrequency ablation sessions in 420 patients: a single center’s experiences. AJR Am J Roentgenol 197:W576–W580CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York and the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) 2015

Authors and Affiliations

  • Jens Ricke
    • 1
  • Julian H. W. Jürgens
    • 1
  • Frederic Deschamps
    • 2
  • Lambros Tselikas
    • 2
  • Katja Uhde
    • 1
  • Ortrud Kosiek
    • 1
  • Thierry De Baere
    • 2
  1. 1.Department of Radiology and Nuclear MedicineUniversity of MagdeburgMagdeburgGermany
  2. 2.Department of Image Guided TherapyInstitut de Cancérologie Gustave RoussyVillejuifFrance

Personalised recommendations